Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 877 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Endocrine Clear all

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Continuous glucose monitoring system; Device
Lead sponsor: Senseonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Escondido, California • Walnut Creek, California • Renton, Washington

Conditions: Breast Cancer
Interventions: Phone interview; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gestational Diabetes
Interventions: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Hypertension, Diabetes
Interventions: Home monitoring; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Interventions: Endocrine Therapy, Biopsy of breast, Neratinib, Biospecimen Collection, Mammogram, Magnetic Resonance Imaging, Breast Surgery, Ultrasound; Procedure · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 5
States / cities: Atlanta, Georgia • Pittsburgh, Pennsylvania • Nashville, Tennessee + 2 more

Conditions: Diabetes, Type 1 Diabetes
Interventions: Unified protocol for cognitive behavioral therapy (UP-CBT), Continuous Glucose Monitoring (CGM); Behavioral · Device
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • The Bronx, New York

Conditions: Obesity, Compensated Cirrhosis, Sarcopenia
Interventions: Continuous Energy Restriction (CER), Alternate Day Modified Fasting (ADMF), Group Health Education Sessions, Late Evening Snack, Physical activity, Self-monitoring, Remotely Supervised Exercise Sessions; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Musculoskeletal and Metabolic Crosstalk
Interventions: Resistance Training, No Resistance Training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 7 Years to 12 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 45
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more

Conditions: Breast Cancer
Interventions: Letrozole, Tamoxifen, Palbociclib, Endocrine Therapy; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 11
States / cities: Stamford, Connecticut • Brewer, Maine • Boston, Massachusetts + 5 more

Conditions: Obese But Otherwise Healthy Participants
Interventions: CRB-913, Placebo; Drug
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Chandler, Arizona • Rancho Cucamonga, California + 12 more

Conditions: Postpartum Depression
Interventions: Estradiol, Placebo, Progesterone, leuprolide acetate; Drug · Other
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions: Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp; Other
Lead sponsor: Yale University; Other
Eligibility: 12 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: Ribociclib, Adjuvant endocrine therapy, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more

Conditions: Type 2 Diabetes
Interventions: SMBG to guide clinical decisions, SMBG and CGM; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Invasive Lobular Carcinoma (mILC)
Interventions: circulating tumor DNA (ctDNA); Diagnostic Test
Lead sponsor: Julia Foldi; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: EXTEND Plus, EXTEND; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 1 Diabetes Mellitus
Interventions: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, Continuous Subcutaneous Insulin Infusion; Device
Lead sponsor: University of Virginia; Other
Eligibility: 6 Years to 18 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Stanford, California • Aurora, Colorado • Charlottesville, Virginia

Conditions: Health Behavior, Obesity
Interventions: SMS Text Messages & Fitbit One, Fitbit One Only; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 69 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Cancer; Chemotherapy
Interventions: COVID antibody titers in the blood; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity
Interventions: Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET; Other · Drug · Device
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes
Interventions: Oral Glucose Tolerance Test; Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Regular Insulin, Humalog; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced or Metastatic ER+ Breast Cancer
Interventions: LSZ102, LEE011, BYL719; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Search by objective public record fields.

PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm

Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds

Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia

Using Health Information Technology (HIT) to Improve Ambulatory Chronic Disease Care: Smart Device Substudy

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression

OPTIMIzing muScle Preservation in paTients wIth Cirrhosis

Effect of Resistance Training on Musculoskeletal Endocrine Interactions

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

The Role of Hormones in Postpartum Mood Disorders

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

Expanding Technology-Enabled Nurse Delivered Chronic Disease Care

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

Fitbit One and Text Messaging Prompts to Promote Physical Activity in Overweight/Obese Adults

Immunological Responses of COVID-19 Vaccination

Reduced Carbohydrate Versus Fat in Obese Subjects

Pharmacogenetics of Response to Sitagliptin (PRS)

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers